File size: 69,594 Bytes

---

tags:
- sentence-transformers
- sentence-similarity
- feature-extraction
- generated_from_trainer
- dataset_size:92934
- loss:MatryoshkaLoss
- loss:MultipleNegativesRankingLoss
base_model: sentence-transformers/all-MiniLM-L6-v2
widget:
- source_sentence: aprepitant prevention chemotherapy induce nausea vomit cinv0869130complete.
    The purpose of this study is to assess the efficacy and safety of recombinant
    human tissue plasminogen kinase derivatives for injection and alteplase in the
    treatment of patients with acute ischemic stroke within 4.5 hours.
  sentences:
  - Coronary Artery Diseases|Multivessel Coronary Artery Disease|Heart Diseases|Cardiovascular
    Diseases inclusion criteria1 patient 1 stenosis angiographic visually determine
    de novo lesion 50 d 3 major epicardial territory lad andor branch cx andor branch
    rca andor branch supply viable myocardium left main involvement2 patient hypoplastic
    rca absence descend posterior presence lesion lad cx territory include trial 3vd
    equivalent3 vessel size 15 mm diameter visually assess diagnostic angiogram4 patient
    chronic stable angina stabilize acute coronary syndrome inclusion criterion syntax
    study     stable canadian cardiovascular society class 1 2 3 4 angina pectoris    unstable
    braunwald class ib ic iib iic iiib iiic angina pectoris ischemia normal cardiac
    enzyme value prior enrollment    patient atypical chest pain asymptomatic provide
    myocardial ischemia eg treadmill exercise test radionuclide scintigraphy stress
    echocardiography5 anatomical syntax score eligible6 patient amenable msct coronary
    angiography eg claustrophobia high heartrate amenable betablocker poor renal function
    etc discretion investigator7 patient inform nature study agree provision provide
    write informed consent approve ethical committee respective clinical siteexclusion
    criteria1 age 18 years2 unable informed consent3 know pregnancy time enrolment
    female childbeare potential menstruation 12 month take adequate contraceptive
    female breastfeed time enrolment4 prior pci cabg history coronary stent implantation5
    evidence evolve ongoing acute myocardial infarction ami ecg andor elevated cardiac
    biomarker accord local standard hospital practice return normal limit time enrollment6
    concomitant cardiac valve disease require surgical therapy reconstruction replacement7
    single twovessel disease time heart team consensus8 atrial fibrillation significant
    arrhythmias9 know allergy iodinate contrast10 body mass index bmi 35 greater11
    participation trial investigational drug device interrater agreement revascularization
    strategy heart team angiofirst algorithm ct algorithm interrater agreement assess
    cohens kappa kappa revascularization strategy heart team angiofirst algorithm
    base invasive syntax score ii ctfirst algorithm base noninvasive syntax score
    ii ffrct 95 confidence interval ci heart team meeting take place average 1 2 week
    afer patient enrollment level agreement decision make strategy base ct functional
    assessment decision make strategy base ct functional assessment ct algorithm group
    screen analysis nov 2017level agreement decision make strategy base ct functional
    assessment decision make strategy base ct functional assessment conventional angiography
    ct algorithm group screen analysis nov 2017level agreement decision make strategy
    base conventional angiography decision make strategy base ct functional assessment
    conventional angiography angio algorithm group screen analysis nov 2017interrater
    agreement revascularization strategy base conventional angiography ct functional
    assessment heart team angiofirst algorithm ctfirst algorithm screen analysis nov
    2017anatomical syntax score calculation base noninvasive ge revolution ct visual
    heart team involve experienced coronary ct reader result syntax score ii screen
    analysis nov 2017anatomical syntax score calculation base noninvasive ge revolution
    ct visual core lab result syntax score ii screen analysis nov 2017anatomical syntax
    score calculation base invasive angiography visual heart team result syntax score
    ii screen analysis nov 2017anatomical syntax score calculation base invasive angiography
    visual core lab result syntax score ii screen analysis nov 2017ct base functional
    anatomy ffrct assess heartflow screen analysis nov 2017concordance syntax score
    strategy screen analysis nov 2017agreement coronary stenosis segment revascularize
    strategy screen analysis nov 2017
  - 'HIV Infections inclusion criterion 20 20 ideal weight height estimate frame size

    good health clinically significant abnormal finding physical examination medical

    history laboratory testsexclusion criterion history clinically significant disease

    history clinically significant allergy include drug allergy participate clinical

    trial 3 month prior study entry hiv infect hepatitis b c virus infect active significant

    infection prior exposure allergy know hypersensitivity pro 140 safety tolerability

    pro 140 60 day '
  - "Chemotherapy-Induced Nausea and Vomiting inclusion criterion patient naive emetogenic\

    \ chemotherapy histologically cytologically confirm malignant disease schedule\

    \ receive single dose moderately emetogenic chemotherapy study day 1 karnofsky\

    \ score 60 greaterexclusion criterion patient schedule receive dose cisplatin\

    \ patient receive abdominal pelvic radiation week prior 6 day initiation chemotherapy\

    \ allergy study drug antiemetic take cyp3a4 substratesprohibite medication significant\

    \ medical mental condition abnormal laboratory value platelet absolute neutrophil\

    \ ast alt bilirubin creatinine number patient report vomiting number patient report\

    \ vomiting overall phase cycle \n\n 1 overall phase 0120 hour post initiation\

    \ mec cycle 1 number patient report complete response number patient report complete\

    \ response vomiting use rescue medication overall phase cycle 1 overall phase\

    \ 0120 hour post initiation mec cycle 1"
- source_sentence: eribulin mesylate phase iv clinical trial korean patient metastatic
    locally advanced breast cancer. This study will treat patients with Metastatic
    Castration Resistant Prostate Cancer who have progressed following prior therapy.
    This is the first time this drug has ever been tested in patients, and so it will
    help to understand what type of side effects may occur with the drug treatment.
    It will also measure the the levels of drug in the body and preliminarily assess
    its anti-cancer activity as monotherapy.
  sentences:
  - End Stage Renal Disease inclusion criterion esrd patient age 18   80 year clinically
    stable judge treat physician 30 day prior enrollment demonstrate pertinent patient
    medical history physical examination laboratory testing hemodialysis therapy hdf
    3 month immediately prior study enrollmentexclusion criterion inform consent provide
    significant psychiatric disorder mental disability condition interfere patient
    ability provide informed consent pregnant breastfeeding planning pregnant unstable
    vascular access associate risk low variable extracorporeal blood flow rate qb
    chronic liver disease know paraproteinassociate disease know bleed disorder eg
    gastrointestinal bleed colonic polyp small bowel angiodysplasia active peptic
    ulcer major bleeding episode ie soft tissue bleed blood stool joint damage retinal
    bleed extensive mucosal bleed exsanguination cerebral hemorrhage   12 week prior
    enrollment blood red blood cell transfusion   12 week prior enrollment clinical
    sign acute infection   4 week prior enrollment active cancer basal cell squamous
    cell skin cancer positive serology test human immunodeficiency virus hepatitis
    infection schedule plan intervention require hospitalization   1 week schedule
    livingdonor transplantation study period currently participate interventional
    clinical study participate interventional clinical study past 3 month interfere
    study reduction ratio lambda immunoglobulin free light chain λflc week 12reduction
    ratio kappa immunoglobulin free light chain kflc week 12reduction ratio chitinase3like
    protein 1 ykl40 week 12reduction ratio fibroblast growth factor 23 fgf23 week
    12reduction ratio serum beta2 microglobulin β2 m week 12 change baseline midweek
    predialysis serum level λflc κflc ykl40 fgf23 ß2 m week 12 24change baseline midweek
    predialysis serum level pentraxin3 ptx3 high sensitivity creactive protein hscrp
    interleukin il6 interleukin10 il10 week 12 24percent change pre postdialysis midweek
    serum level hscrp week 12percent change pre postdialysis midweek serum level ptx3
    week 12percent change pre postdialysis midweek serum level il6 week 12percent
    change pre postdialysis midweek serum level il10 week 12change baseline midweek
    predialysis serum level fibrinogen week 12 24change baseline midweek predialysis
    serum level albumin week 12 24single pool ktvurea week 24serum phosphorous week
    24kidney disease quality life 36 kdqol36 baseline week 12 week 24dialysis symptom
    index dsi baseline week 12 week 24serum ferritin baseline week 12 week 24transferrin
    saturation tsat baseline week 12 week 2424hour urine output monthly basis month
    1 month 2 month 3 month 4 month 5 month 6erythropoiesis stimulate agent esa responsiveness
    baseline week 4 week 8 week 12 week 16 week 20 week 24hemoglobin level baseline
    week 4 week 8 week 12 week 16 week 20 week 24esa dosage type administration frequency
    route baseline week 4 week 8 week 12 week 16 week 20 week 24intravenous iron dosage
    baseline week 4 week 8 week 12 week 16 week 20 week 24number adverse event hospitalization
    cardiovascular event infective episode week 1 week 24total patient death week
    1 week 24
  - Skin Laxity inclusion criterion male female subject age 18   75 year old asa physical
    status classification system class class ii subject complaint skin laxity line
    low eyelid area understand accept obligation undergo procedure treatment area
    treat study participation absence physical condition unacceptable investigator
    female childbeare potential sexually active willing use approve method birth control
    study participation willing able comply protocol requirement include studyrequired
    imagesphotos assessmentsmeasurement return followup visit willing release right
    use study photo include publication able read understand sign date inform consent
    able communicate site video andor photograph event virtual followup visitexclusion
    criterion subject present asa physical status classification system class iii
    high festoon periorbital area prior cosmeticaesthetic filler hyaluronic acid polyllactic
    acid calcium hydroxylapatite et study treatment area past 12 month pregnant lactating
    plan pregnant study participation know hypersensitivity allergy tumescent anesthetic
    lidocaine epinephrine know hypersensitivity allergy ibuprofen nsaid previous surgery
    study treatment area active systemic local skin disease alter wound heal significant
    uncontrolled medical condition opinion investigator participation study compromise
    patient health history autoimmune disease exclude hashimotos thyroiditis know
    susceptibility keloid formation hypertrophic scar cancerous precancerous lesion
    area treat possess surgically implant electronic device ie pacemaker mental health
    illness dementia schizophrenia psychiatric hospitalization past year participation
    investigational study 30 day prior consent study participation subject opinion
    investigator appropriate candidate study day 180 number participant improvement
    low eyelid area determine mask qualitative assessment improvement low eyelid area
    determine mask qualitative assessment photograph 180days posttreatment compare
    baseline blind independent reviewer improvement assess base photograph take visit
    site 2d camera system 180day day 90 number participant improvement low eyelid
    area determine mask qualitative assessment improvement low eyelid area determine
    mask qualitative assessment photograph 90days posttreatment compare baseline blind
    independent reviewer improvement assess base photograph take visit site 2d camera
    system 90day
  - Breast Neoplasms|Breast Cancer inclusion criteria1 female age great equal 20 years2
    patient histologically cytologically confirm carcinoma breast3 patient locally
    advance metastatic carcinoma breast4 patient receive prior chemotherapeutic regimen
    include antracycline taxane 2 regimen locally recurrent andor metastatic disease5
    patient prove refractory recent chemotherapy 6 month therapy6 patient assessable
    lesion accord recist v 117 adequately maintain bone marrow function     absolute
    neutrophil count anc great equal 15 x 109 l    hemoglobin great equal 100 gdl
    hemoglobin 100 gdl acceptable correct erythropoietin transfusion    platelet count
    great equal 100 x 109 l8 adequately maintain liver function     total bilirubin
    equal 15 time upper limit normal uln    alkaline phosphatasealp alanine aminotransferase
    alt aspartate aminotransferase ast equal 3 x uln case liver metastasis equal 5
    x uln9 adequately maintain renal function     serum creatinine equal 20 mgdl    calculate
    creatinine clearance great equal 40 mlmin cockcroft gault formula10 resolution
    chemotherapy radiationrelated toxicity grade 1 severity low      alopecia     stable
    sensory neuropathy equal grade 211 eastern cooperative oncology group ecog performance
    status 0 212 life expectancy great equal 3 months13 patient willing able comply
    study protocol duration study14 patient provide write consent participate studyexclusion
    criteria1 patient receive chemotherapy radiation biologic immunotherapy hormonal
    therapy week treatment start palliative radiation enrolled2 pulmonary lymphangitic
    involvement result pulmonary dysfunction require active treatment include use
    oxygen3 patient brain subdural metastasis eligible complete local therapy discontinue
    use corticosteroid indication week start treatment study sign andor symptom brain
    metastasis stable week start study treatment4 patient meningeal carcinomatosis5
    significant cardiovascular impairment     myocardial infarction past month unstable
    angina history congestive heart failure nyha class iii iv cardiac arrhythmia    qtc
    prolongation bazetts formula great 480 msec congenital long qt syndrome6 severeuncontrolle
    intercurrent illnessinfection require administration antibiotic injection7 patient
    process major surgery week participation clinical trial8 patient prior malignancy
    past year breast cancer treat nonmelanoma skin cancer carcinoma situ cervix excluded9
    patient know positive hiv status10 patient receive genetic therapy investigational
    drug 4 week treatment start expect receive prohibit medication11 patient prior
    allergy halichondrin b derivative active ingredient diluting agent12 patient receive
    investigational product registration study13 patient pregnant possibly pregnant
    lactating14 patient agree practice contraception study periods15 patient participate
    clinical trial 4 week screening16 patient judge investigator sub investigator
    unsuitable inclusion number participant treatmentemergent adverse event teae treatmentemergent
    adverse event sae ae define harmful untoward sign include abnormal laboratory
    value etc symptom disease participant administer investigational product necessarily
    causal relationship treatment sae define ae life threaten result death result
    hospitalization initial prolonged result disability significant persistent permanent
    change impairment damage disruption participant body functionstructure physical
    activity quality life result congenital anomaly require intervention prevent permanent
    impairment damage teaes define event start date time administration dose study
    drug event present prior administration dose study drug increase severity study
    mean 376 month disease control rate dcr dcr define number participant complete
    response cr partial response pr stable disease sd response evaluation criterion
    solid tumor recist version 11 assess tumor response tumor response evaluate investigator
    cr define disappearance extranodal target lesion pathological lymph node decrease
    10 millimeter mm short axis pr define 30 decrease sum long diameter sld target
    lesion take reference baseline sum diameter sd define sufficient shrinkage qualify
    pr sufficient increase qualify progressive disease sld increase 20 small value
    study include baseline small sld demonstrate absolute increase 5 mm lesion increase
    2 mm 3 mm example qualify mean 376 month
- source_sentence: 'safety study mt4666 subject alzheimer disease. This is a phase

    1, randomized, open label, single-dose, replicate crossover clinical trial to

    compare the safety and pharmacokinetics of YH22162 in healthy male volunteers.





    Hypothesis: Study drug and comparator drug are showing equal pharmacokinetics.'
  sentences:
  - Alzheimer's Disease inclusion criterion probable alzheimer disease consistent
    national institute aging alzheimers association criterion diagnosis alzheimer
    disease mckhann et al 2011 mmse score   14   24 screening   12   26 baseline modify
    hachinski ischemic score mhis   4 screening appropriate caregiver available subject
    live home facility require continuous 24hour nursing careexclusion criterion diagnosis
    disease cause dementia diagnosis major depressive disorder define diagnostic statistical
    manual mental disorder fourth edition text revision dsmivtr year history current
    diagnosis psychosis history myocardial infarction unstable angina month screen
    history cerebrovascular disorder 18 month screen complication hepatic disorder
    renal dysfunction safety 2 fix dose evp6124 subject alzheimer disease criterion
    evaluation include adverse event clinical laboratory test vital sign body weight
    12lead ecg columbia suicide severity rating scale cssrs week 56 change mini mental
    state examination mmse baseline week 52change neuropsychiatric inventory npi total
    score baseline week 52
  - 'Type 2 Diabetes inclusion criteria1 man nonpregnant woman 2865 year age2 diagnose

    t2d 3 years3 a1c 75   95 5980 mmolmol4 bmi   28   40 kgm25 oral oad metformin

    plus additional oad note half maximum label dose high tolerate change medication

    12 week prior screening visit visit 1 refer ada standard medical care diabetes

    2018 table 83 maximum approve daily dose noninsulin glucose lower agent 43 note

    subject sulfonylurea su glucoselowere drug diabetes sus permit study glipizide

    glimepiride dose half maximum label dosing exclusion study entry patient unwilling

    reduce dose su time dmr procedure describe protocol excluded6 agree use additional

    glucoselowere treatment eg liraglutide oad exception glyburide recommend study

    investigator case persistent hyperglycemia7 agree donate blood participation study8

    able comply study requirement understand sign inform consent form9 woman childbeare

    potential wocbp acceptable method contraception study10 woman breastfeedingexclusion

    criteria1 diagnose type 1 diabetes t1d2 history diabetic ketoacidosis hyperosmolar

    nonketotic coma3 probable insulin production failure define fast c peptide serum

    1 ngml 333pmoll4 previous use type insulin 1 month time treatment gestational

    diabetes5 current use injectable medication diabetes insulin glp1ra6 current use

    glyburide sulfonylurea su glucoselowere drug diabetes7 hypoglycemia unawareness

    history severe hypoglycemia 1 severe hypoglycemic event define need thirdpartyassistance

    year8 know autoimmune disease include limit celiac disease preexist symptom systemic

    lupus erythematosus scleroderma autoimmune connective tissue disorder9 previous

    gi surgery limit treatment duodenum bilroth 2 rouxeny gastric bypass similar procedure

    conditions10 history chronic acute pancreatitis11 history diabetic gastroparesis12

    know active hepatitis active liver disease13 acute gastrointestinal illness previous

    7 days14 know history irritable bowel syndrome radiation enteritis inflammatory

    bowel disease crohns disease15 know history structural functional disorder esophagus

    impede passage device gastrointestinal tract increase risk esophageal damage endoscopic

    procedure include barretts esophagus esophagitis dysphagia achalasia stricturestenosis

    esophageal varix esophageal diverticula esophageal perforation disorder esophagus16

    know history structural functional disorder esophagus include swallowing disorder

    esophageal chest pain disorder drug refractory esophageal reflux symptoms17 know

    history structural functional disorder stomach include gastroparesis gastric ulcer

    chronic gastritis gastric varix hiatal hernia   2 cm cancer disorder stomach18

    know history chronic symptom suggestive structural functional disorder stomach

    include symptom chronic upper abdominal pain chronic nausea chronic vomiting chronic

    dyspepsia symptom suggestive gastroparesis include postprandial fullness pain

    postprandial nausea vomiting early satiety19 know history duodenal ulcer intestinal

    diverticula diverticulitis intestinal varix intestinal stricturestenosis small

    bowel obstruction obstructive disorder gi tract20 currently ongoing symptom suggestive

    intermittent small bowel obstruction recurrent bout postprandial abdominal pain

    nausea vomiting21 active h pylori infection subject active h pylori continue screening

    process treat appropriate antibiotic regimen22 history coagulopathy upper gastrointestinal

    bleeding condition ulcer gastric varix stricture congenital acquire intestinal

    telangiectasia23 current use anticoagulation therapy warfarin discontinue 7 day

    14 day procedure24 current use p2y12 inhibitor clopidogrel pasugrel ticagrelor

    discontinue 14 day 14 day procedure25 unable discontinue nonsteroidal antiinflammatory

    drug nsaid treatment 4 week follow procedure use low dose aspirin allowed26 current

    use serotonergic medication ssri27 use systemic glucocorticoid exclude topical

    ophthalmic application inhale form 10 consecutive day 90 day prior screening visit28

    use drug know affect gi motility eg metoclopramide29 receive weight loss medication

    meridia xenical counter weight loss medications30 untreatedinadequately treat

    hypothyroidism define elevated thyroidstimulating hormone tsh level screen thyroid

    hormone replacement therapy stable dose 6 week prior screening31 persistent anemia

    define hemoglobin 10 gdl32 subject donate blood receive transfusion prior 3 months33

    subject condition alter red blood cell turnover34 subject prosthetic joints35

    significant cardiovascular disease include know history valvular disease myocardial

    infarction heart failure transient ischemic attack stroke 6 months36 moderate

    severe chronic kidney disease ckd estimate glomerular filtration rate egfr 45

    mlmin173m2 estimate mdrd37 know immunocompromise status include limit individual

    undergo organ transplantation chemotherapy radiotherapy past 12 month clinicallysignificant

    leukopenia positive human immunodeficiency virus hiv immune status make subject

    poor candidate clinical trial participation opinion investigator38 active systemic

    infection39 active malignancy 5 year exception treat basal cell treat squamous

    cell carcinoma40 subject personal family history medullary thyroid carcinoma41

    subject multiple endocrine neoplasia syndrome type 242 candidate surgery general

    anesthesia43 active illicit substance abuse alcoholism44 current smoker45 participate

    ongoing clinical trial investigational drug device46 mental physical condition

    opinion investigator make subject poor candidate clinical trial participation47

    unwilling unable perform smbg complete patient diary comply study visit study

    procedure require protocoladditional exclusion criterion confirm screening process1

    a1c post runin phase   75 59 mmolmol   95 86 mmolmol2 severe hypoglycemic event

    define hypoglycemia require thirdparty assistance clinically significant hypoglycemic

    event define selfmonitored laboratory plasma glucose level   54 mgdl 30 mmoll   2

    glucose alert value 70 mgdl 39 mmoll clear correctable precipitating factor identify

    screening visit visit 13 uncontrolled hyperglycemia glucose level 270 mgdl 15

    mmoll overnight fast 360 mgdl 20 mmoll randomly perform measurement medication

    runin period confirm second measurement day4 mean 3 separate blood pressure measurement

    180 mmhg systolic 100 mmhg diastolic5 wocbp positive urine pregnancy test baseline

    visit6 active uncontrolled gerd define grade iii esophagitis greater7 abnormality

    gi tract prevent endoscopic access duodenum8 anatomic abnormality duodenum preclude

    completion dmr procedure include tortuous anatomy9 malignancy newly diagnose endoscopy10

    upper gastrointestinal condition ulcer polyp varix stricture congenital acquire

    intestinal telangiectasia change hemoglobin a1c hba1c change hba1c baseline dmr

    vs sham group 24 week post procedure '
  - Solid Tumors inclusion criteria1 male female age   18 years2 histologically cytologically
    confirm nonhematologic malignancy3 eastern cooperative oncology group ecog performance
    score 024 adequate bone marrow renal hepatic function follow     bone marrow absolute
    neutrophil count anc   1500mm3 platelet   100000mm3   hemoglobin   90 gdl    renal
    function serum creatinine   20 mgdl    hepatic function ast alt   15 x uln liver
    metastasis present ast alt   50 x uln bilirubin   15 mgdl5 ptt   15 x uln andor
    inr   156 woman childbeare potential man agree use adequate contraception follow
    list prior study entry duration study participation 90 day follow completion therapy
    woman childbeare potential negative urine pregnancy test 7 day prior initiation
    treatment andor post menopausal woman amenorrheic 12 month consider nonchildbeare
    potential     total abstinence sexual intercourse minimum complete menstrual cycle    vasectomize
    male subject vasectomized partner female subject    hormonal contraceptive oral
    parenteral transdermal 3 month prior study drug administration subject currently
    hormonal contraceptive use barrier method study 1 month study completion    intrauterine
    device iud    double barrier method condom contraceptive sponge diaphragm vaginal
    ring spermicidal jelly cream    additionally male subject include vasectomize
    partner pregnant pregnant agree use condom duration study 90 day follow completion
    therapy7 capable understanding comply parameter outline protocol able sign inform
    consent approve independent ethic committee iecinstitutional review board irb
    prior initiation screening studyspecific proceduresexclusion criteria1 receive
    anticancer therapy include investigational agent cytotoxic chemotherapy radiation
    therapy biologic therapy 21 day period define 5 half life whichever short prior
    study drug administration addition subject recover equal grade 1 clinically significant
    adverse effectstoxicitie previous therapy2 undergo major surgery 21 day study
    day 13 untreated brain meningeal metastasis subject treat brain metastasis radiographically
    clinically stable 4 week therapy evidence cavitation hemorrhage brain lesion eligible
    provide asymptomatic require corticosteroid discontinue steroid 1 week prior study
    day 14 central thoracic tumor lesion define location involve abut hilar structure
    presence central nodal disease allowed5 female subject pregnant breastfeeding6
    receive potential inhibitor metabolism linifanib 21 day prior initial study drug
    administration drug include cyp3a inhibitor eg triazole itraconazole ketoconazole
    fluconazole grapefruit juice verapamil diltiazem aprepitant clarithromycin erythromycin
    cyp1a2 inhibitor eg fluvoxamine ciprofloxacin mexiletine propafenone zileuton
    cyp2c19 inhibitor eg omeprazole cyp2c8 substrate eg repaglinide paclitaxel rosiglitazone
    cyp3a inducer eg rifampin carbamazepine7 proteinuria define national cancer institute
    common terminology criterion adverse event nci ctcae grade   1 baseline measure
    urine dipstick 2 great confirm 24 hour urine collection   1 g24 hrs subject rescreene
    proteinuria show control intervention8 currently exhibit symptomatic persistent
    uncontrolled hypertension define diastolic blood pressure bp   100 mmhg systolic
    blood pressure bp   150 mmhg subject rescreene bp show control intervention9 clinically
    significant uncontrolled condition include limit     active uncontrolled infection    class
    iii iv heart failure define new york heart association functional classification
    system    unstable angina pectoris cardiac arrhythmia    myocardial infarction
    6 month    history adrenal insufficiency    history cerebral vascular accident
    6 month    active ulcerative colitis crohns disease celiac disease condition interfere
    absorption    history autoimmune disease kidney involvement    history overt bleeding   30
    ml bleedingepisode 3 month study drug administration    psychiatric illnesssocial
    situation limit compliance study requirement    medical condition opinion study
    investigator place subject unacceptably high risk toxicities10 receive combination
    antiretroviral therapy human immunodeficiency virus hiv11 consume grapefruit grapefruit
    product 21 day prior initial study drug administration12 document leave ventricular
    lv ejection fraction   50 investigate effect ketoconazole pharmacokinetic abt869
    subject advanced metastatic solid tumor blood sample pk abt869 ketoconazole collect
    designate time point study different timepoint day 112 safety adverse event   number
    participant adverse event report measure safety adverse event monitor lab test
    assessment physical exam vital sign evaluate study study
- source_sentence: effect adhesive overlay delivery contraceptive hormone ortho evra
    healthy woman. This is A Randomized, Blinded, Placebo- and Positive-Controlled,
    Four-Period, Crossover-Design Thorough QT/QTc (TQT) Study to Evaluate the Effect
    of Orelabrutinib on Cardiac Repolarization in Healthy Subjects
  sentences:
  - 'Alagille Syndrome inclusion criteria1 inform consent assent provide applicable

    institutional review board irb ethic committee ec2 clinical andor genetic diagnosis

    algs3 male female participant age 12 month 5 kg clinically significant cholestatic

    pruritus associate algs4 willingness adhere acceptable method contraception treatment

    discontinuation female childbeare potential sexually active sexually active program5

    therapeutic option access ongoing algs clinical trialsexclusion criteria1 diagnosis

    cholestatic liver disease algs2 female pregnant breastfeeding3 clinically significant

    cardiovascular hepatic gastrointestinal pulmonary neurologic infectious renal

    disease medical condition opinion physician medical monitor preclude participation

    program4 past medical history compensate decompensate cirrhosis5 presence disease

    condition know interfere absorption distribution metabolism excretion maralixibat

    mode action  '
  - Myopia|Refractive Error inclusion criterion willing able sign informed consent
    document legal age consent legally authorize representative sign informed consent
    document able achieve well correct visual acuity bcva 2025 snellen well eye distance
    manifest cylinder equal 075 diopter eye wear contact lense protocoldefine specification
    require spherical contact lense available range power protocoldefine inclusion
    criterion applyexclusion criterion eye condition contraindicate contact lens wear
    systemic ocular abnormality infection disease likely affect successful wear contact
    lense use accessory solution moderate severe ocular finding examination use systemic
    ocular medication contraindicate contact lens wear include use topical ocular
    medication require instillation contact lens wear approve lubricating drop habitual
    lense wear extended wear modality routinely sleep lense overnight 1 night week
    3 month prior enrollment previous corneal refractive surgery irregular cornea
    eye injury surgery 6 month exclude placement punctal plug monovision monocular
    subject eye functional vision subject fit lens history intolerance hypersensitivity
    component test article protocoldefine exclusion criterion apply subjective rating
    overall satisfaction overall satisfaction rate participant 10point scale 1 dissatisfied
    10 satisfied participant rate eye provide single rating day 7 positive purchase
    intent report questionnaire response assume lense price expect pay likely purchase
    lense binary positive vs negative response variable derive 5point likert scale
    positive purchase intent report percentage participant choose definitely purchase
    probably purchase day 7
  - Healthy Volunteers inclusion criterion sign informed consent body mass index bmi
    18 30 kgm2 inclusive body weight 50 kg 90 kg surgically sterile intact ovary abstinent
    sexually active practice effective method nonhormonal birth control eg nonhormonal
    intrauterine device doublebarrier method male partner sterilization entry study
    complete term pregnancy 90 day admission study site history regular menstrual
    cycle occur 25 35 day pregnant lactating blood pressure 90 140 mmhg systolic inclusive
    high 90 mmhg diastolic hemoglobin equal 120 screeningexclusion criterion history
    smoking use nicotinecontaine substance steroid hormonal therapy 30 day admission
    study receive depo provera injection 6 month admission study history presence
    disorder commonly accept contraindication sex hormonal therapy history current
    clinically significant medical illness condition investigator consider exclude
    patient interfere interpretation study result ngmn plasma concentration period
    1 2 0 24 48 72 120 168 171 174 180 192 204 216 240 hoursee plasma concentration
    period 1 2 0 24 48 72 120 168 171 174 180 192 204 216 240 hour pharmacokinetic
    parameter ngmn period 1 2 pharmacokinetic parameter ngmn measure auc cmax tmax
    css 0 24 48 72 120 168 171 174 180 192 204 216 240 hourspharmacokinetic parameter
    ee period 1 2 pharmacokinetic parameter ee measure auc cmax tmax css 0 24 48 72
    120 168 171 174 180 192 204 216 240 hoursincidence adverse event measure safety
    tolerability approximately 2 monthsthe number patient change clinical laboratory
    test value physical examination result vital sign measurement approximately 2
    month
- source_sentence: 'open label trial safety efficacy sym001 treatment immune thrombocytopenic

    purpura itp. If your serious vaccine-induced adverse event has been entered in

    the CDC Vaccine Adverse Event Reporting System (VAERS) we are interested in enrolling

    you for this study in order to log your symptoms.





    The primary goal of this study is to create a national database and gather vaccine-associated

    serious adverse events/injury data from newly vaccinated individuals in the US

    in order to identify the possible underlying causal relationships and plausible

    underlying biological mechanisms. The project aims to identify the genetic determinants

    of vaccine-induced adverse response by studying host genetics. We plan to use

    whole genome sequencing to identify single nucleotide polymorphisms associated

    with cardiovascular, neurological, gastrointestinal, musculoskeletal and immunological

    symptoms induced by vaccine administration.





    The secondary goal is to establish criteria that enable classification of vaccine-induced

    adverse events/injuries compare data from our database with the official Vaccine

    Injury Table National Vaccine Injury Compensation Program on or after March 21,

    2017.





    The tertiary goal is to establish a database to gather detailed long-term adverse

    reaction data from subjects enrolled in FDA Emergency Use Authorized vaccine clinical

    trials.'
  sentences:
  - Immune Thrombocytopenic Purpura inclusion criterion confirm presence thrombocytopenia
    platelet count   30000mm3 predose visit history isolated itp rhdpositive serology
    previous treatment response line therapy itpexclusion criterion know clinical
    picture suggestive cause thrombocytopenia especially systematic lupus erythematosusantiphospholipid
    syndrome evans syndrome immunodeficiency state lymphoproliferative disorder liver
    diseaseingestion drug quinidinequinine heparin sulfonamide hereditary thrombocytopenia
    confirm relevant laboratory finding suspect infection hiv hepatitis c h pylori
    clinical splenomegaly history abnormal bone marrow examination ongoing haemorrhage
    correspond grade 3 4 bleeding scale underlie haemolytic condition history splenectomy
    subject pregnant breast feeding intend pregnant incidence severity adverse event
    aes include adverse event saes 6 week post dose measurement platelet count day
    1 week 6
  - Type 2 Diabetes Mellitus inclusion criterion patient complete doubleblind base
    study mk043106400nct00397631 75 compliance study medication base study treatment
    period woman childbeare potential continue comply protocolspecifie contraceptive
    method change baseline ie week 0 24week base study hemoglobin a1c hba1c week 54
    hba1c measure percent change baseline reflect week 54 hba1c percent minus week
    0 hba1c percent baseline 54 week change baseline ie week 0 24week base study fast
    plasma glucose fpg week 54 change baseline week 54 define week 54 minus week 0
    baseline week 54
  - Multiple System Atrophy inclusion criteriadiagnostic1 participant diagnosis possible
    probable msa modify gilman et al 2008 diagnostic criteria2 participant onset msa
    symptom occur 4 year screen assess investigator3 evidence msa specific symptom
    deficit measure umsars scaleexclusion criteriamedical history1 participant contraindication
    study proceduresdiagnostic assessments1 presence confound diagnosis andor condition
    affect participant safety study investigator judgement2 participant participation
    previous study diseasemodifye therapy prove receipt active treatment compromise
    interpretability datum present study consultation medical monitor designeeother1
    participant participate study investigate active passive immunization αsynuclein
    αsyn progressive disease pd msa immunoglobulin g therapy 6 month screen change
    baseline modify unified multiple system atrophy rating scale umsar week 52 umsar
    historical review 11item scale adapt unify parkinson disease rating scale updrs
    assess activity relate motor disability relate autonomic dysfunction item score
    0 normal 3 severe total score sum score domain range 0 33 high score mean poor
    health 52 week change baseline 11item umsar week 52 11 item umsar include 11 item
    ii assess motor autonomic disability umsar historical review assess activity relate
    motor disability autonomic dysfunction umsar ii motor examination measure functional
    impairment specific parkinsonian cerebellar feature item score 0 normal 4 severe
    total score sum score domain range 0 44 high score mean poor health 52 weekschange
    baseline umsar total score umsar   ii week 52 umsar total scale consist item umsars
    part ii umsar historical review 12item scale assess activity relate motor disability
    autonomic dysfunction item score 0 normal 4 severe umsar ii motor examination
    14item scale measure functional impairment eg speech rapid alternate movement
    hand finger tap leg agility select complex movement specific parkinsonian tremor
    rest cerebellar ocular motor dysfunction heelshin test feature item score 0 normal
    4 severe 52 weekschange baseline umsars week 52 umsar historical review modified
    11item scale adapt updrs assess activity relate motor disability 8 item 4 novel
    item relate autonomic dysfunction item score 0 normal 4 severe total score sum
    score item range 0 44 high score mean poor health 52 weekschange baseline umsars
    ii week 52 umsar ii motor examination 14item scale item eg speech rapid alternate
    movement hand finger tap leg agility measure functional impairment select complex
    movement item directly refer specific parkinsonian tremor rest cerebellar ocular
    motor dysfunction heelshin test feature motor examination section umsar base modify
    updrsiii item addition novel item heelkneeshin ataxia item score 0 normal 4 severe
    total score sum score item range 0 56 high score mean poor health 52 weeksclinical
    global impressionseverity cgis score cgis assess clinicians impression participant
    clinical condition clinician use total clinical experience participant population
    rate current severity participant illness 7point scale range 1 normal ill 7 extremely
    ill participant high score mean well health 52 weekschange baseline scale outcome
    parkinson disease   autonomic dysfunction scopaaut total score scopaaut patientreported
    outcome assess autonomic function autonomic function critical symptom domain msa
    scale selfcomplete participant consist 25 item assess follow domain gastrointestinal
    7 item urinary 6 item cardiovascular 3 item thermoregulatory 4 item pupillomotor
    1 item sexual 2 item man 2 item woman score item range 0 experience symptom 3
    experience symptom total composite score include domain report score range 0 symptom
    69 high burden symptom 52 weeksoverall survival os os define time day study drug
    administration death cause 52 weekschange baseline level cerebrospinal fluid csf
    free alphasynuclein αsyn 52 weekscmax maximum observe serum concentration tak341
    predose day 1 29 57 85 169 253 337 multiple timepoint 24 hour postdose day 1 57
    85 169 337 anytime day 365 427 early termination day 57 applicable early pk cohortstmax
    time occurrence cmax serum tak341 predose day 1 29 57 85 169 253 337 multiple
    timepoint 24 hour postdose day 1 57 85 169 337 anytime day 365 427 early termination
    day 57 applicable early pk cohortsaucτ area concentrationtime curve dose interval
    serum tak341 predose day 1 29 57 85 169 253 337 multiple timepoint 24 hour postdose
    day 1 57 85 169 337 anytime day 365 427 early termination day 57 applicable early
    pk cohortscsf concentration tak341 lumbar puncture csf sampling perform predose
    day 1 85 applicable early pk cohort 365number participant adverse event ae adverse
    event ae define untoward medical occurrence participant administer pharmaceutical
    product untoward medical occurrence necessarily causal relationship treatment
    datum report number participant analyze safety parameter include clinically significant
    abnormal value clinical laboratory evaluation vital sign ecg parameters physical
    examination neurological examination columbiasuicide severity rating scale cssrs
    52 weeksnumber participant antidrug antibody 52 week
pipeline_tag: sentence-similarity
library_name: sentence-transformers
---


# SentenceTransformer based on sentence-transformers/all-MiniLM-L6-v2

This is a [sentence-transformers](https://www.SBERT.net) model finetuned from [sentence-transformers/all-MiniLM-L6-v2](https://huggingface.co/sentence-transformers/all-MiniLM-L6-v2). It maps sentences & paragraphs to a 384-dimensional dense vector space and can be used for semantic textual similarity, semantic search, paraphrase mining, text classification, clustering, and more.

## Model Details

### Model Description
- **Model Type:** Sentence Transformer
- **Base model:** [sentence-transformers/all-MiniLM-L6-v2](https://huggingface.co/sentence-transformers/all-MiniLM-L6-v2) <!-- at revision fa97f6e7cb1a59073dff9e6b13e2715cf7475ac9 -->
- **Maximum Sequence Length:** 256 tokens
- **Output Dimensionality:** 384 dimensions
- **Similarity Function:** Cosine Similarity
<!-- - **Training Dataset:** Unknown -->
<!-- - **Language:** Unknown -->
<!-- - **License:** Unknown -->

### Model Sources

- **Documentation:** [Sentence Transformers Documentation](https://sbert.net)
- **Repository:** [Sentence Transformers on GitHub](https://github.com/UKPLab/sentence-transformers)
- **Hugging Face:** [Sentence Transformers on Hugging Face](https://huggingface.co/models?library=sentence-transformers)

### Full Model Architecture

```

SentenceTransformer(

  (0): Transformer({'max_seq_length': 256, 'do_lower_case': False}) with Transformer model: BertModel 

  (1): Pooling({'word_embedding_dimension': 384, 'pooling_mode_cls_token': False, 'pooling_mode_mean_tokens': True, 'pooling_mode_max_tokens': False, 'pooling_mode_mean_sqrt_len_tokens': False, 'pooling_mode_weightedmean_tokens': False, 'pooling_mode_lasttoken': False, 'include_prompt': True})

  (2): Normalize()

)

```

## Usage

### Direct Usage (Sentence Transformers)

First install the Sentence Transformers library:

```bash

pip install -U sentence-transformers

```

Then you can load this model and run inference.
```python

from sentence_transformers import SentenceTransformer



# Download from the 🤗 Hub

model = SentenceTransformer("sentence_transformers_model_id")

# Run inference

sentences = [

    'open label trial safety efficacy sym001 treatment immune thrombocytopenic purpura itp. If your serious vaccine-induced adverse event has been entered in the CDC Vaccine Adverse Event Reporting System (VAERS) we are interested in enrolling you for this study in order to log your symptoms.\n\nThe primary goal of this study is to create a national database and gather vaccine-associated serious adverse events/injury data from newly vaccinated individuals in the US in order to identify the possible underlying causal relationships and plausible underlying biological mechanisms. The project aims to identify the genetic determinants of vaccine-induced adverse response by studying host genetics. We plan to use whole genome sequencing to identify single nucleotide polymorphisms associated with cardiovascular, neurological, gastrointestinal, musculoskeletal and immunological symptoms induced by vaccine administration.\n\nThe secondary goal is to establish criteria that enable classification of vaccine-induced adverse events/injuries compare data from our database with the official Vaccine Injury Table National Vaccine Injury Compensation Program on or after March 21, 2017.\n\nThe tertiary goal is to establish a database to gather detailed long-term adverse reaction data from subjects enrolled in FDA Emergency Use Authorized vaccine clinical trials.',

    'Immune Thrombocytopenic Purpura inclusion criterion confirm presence thrombocytopenia platelet count   30000mm3 predose visit history isolated itp rhdpositive serology previous treatment response line therapy itpexclusion criterion know clinical picture suggestive cause thrombocytopenia especially systematic lupus erythematosusantiphospholipid syndrome evans syndrome immunodeficiency state lymphoproliferative disorder liver diseaseingestion drug quinidinequinine heparin sulfonamide hereditary thrombocytopenia confirm relevant laboratory finding suspect infection hiv hepatitis c h pylori clinical splenomegaly history abnormal bone marrow examination ongoing haemorrhage correspond grade 3 4 bleeding scale underlie haemolytic condition history splenectomy subject pregnant breast feeding intend pregnant incidence severity adverse event aes include adverse event saes 6 week post dose measurement platelet count day 1 week 6',

    'Multiple System Atrophy inclusion criteriadiagnostic1 participant diagnosis possible probable msa modify gilman et al 2008 diagnostic criteria2 participant onset msa symptom occur 4 year screen assess investigator3 evidence msa specific symptom deficit measure umsars scaleexclusion criteriamedical history1 participant contraindication study proceduresdiagnostic assessments1 presence confound diagnosis andor condition affect participant safety study investigator judgement2 participant participation previous study diseasemodifye therapy prove receipt active treatment compromise interpretability datum present study consultation medical monitor designeeother1 participant participate study investigate active passive immunization αsynuclein αsyn progressive disease pd msa immunoglobulin g therapy 6 month screen change baseline modify unified multiple system atrophy rating scale umsar week 52 umsar historical review 11item scale adapt unify parkinson disease rating scale updrs assess activity relate motor disability relate autonomic dysfunction item score 0 normal 3 severe total score sum score domain range 0 33 high score mean poor health 52 week change baseline 11item umsar week 52 11 item umsar include 11 item ii assess motor autonomic disability umsar historical review assess activity relate motor disability autonomic dysfunction umsar ii motor examination measure functional impairment specific parkinsonian cerebellar feature item score 0 normal 4 severe total score sum score domain range 0 44 high score mean poor health 52 weekschange baseline umsar total score umsar   ii week 52 umsar total scale consist item umsars part ii umsar historical review 12item scale assess activity relate motor disability autonomic dysfunction item score 0 normal 4 severe umsar ii motor examination 14item scale measure functional impairment eg speech rapid alternate movement hand finger tap leg agility select complex movement specific parkinsonian tremor rest cerebellar ocular motor dysfunction heelshin test feature item score 0 normal 4 severe 52 weekschange baseline umsars week 52 umsar historical review modified 11item scale adapt updrs assess activity relate motor disability 8 item 4 novel item relate autonomic dysfunction item score 0 normal 4 severe total score sum score item range 0 44 high score mean poor health 52 weekschange baseline umsars ii week 52 umsar ii motor examination 14item scale item eg speech rapid alternate movement hand finger tap leg agility measure functional impairment select complex movement item directly refer specific parkinsonian tremor rest cerebellar ocular motor dysfunction heelshin test feature motor examination section umsar base modify updrsiii item addition novel item heelkneeshin ataxia item score 0 normal 4 severe total score sum score item range 0 56 high score mean poor health 52 weeksclinical global impressionseverity cgis score cgis assess clinicians impression participant clinical condition clinician use total clinical experience participant population rate current severity participant illness 7point scale range 1 normal ill 7 extremely ill participant high score mean well health 52 weekschange baseline scale outcome parkinson disease   autonomic dysfunction scopaaut total score scopaaut patientreported outcome assess autonomic function autonomic function critical symptom domain msa scale selfcomplete participant consist 25 item assess follow domain gastrointestinal 7 item urinary 6 item cardiovascular 3 item thermoregulatory 4 item pupillomotor 1 item sexual 2 item man 2 item woman score item range 0 experience symptom 3 experience symptom total composite score include domain report score range 0 symptom 69 high burden symptom 52 weeksoverall survival os os define time day study drug administration death cause 52 weekschange baseline level cerebrospinal fluid csf free alphasynuclein αsyn 52 weekscmax maximum observe serum concentration tak341 predose day 1 29 57 85 169 253 337 multiple timepoint 24 hour postdose day 1 57 85 169 337 anytime day 365 427 early termination day 57 applicable early pk cohortstmax time occurrence cmax serum tak341 predose day 1 29 57 85 169 253 337 multiple timepoint 24 hour postdose day 1 57 85 169 337 anytime day 365 427 early termination day 57 applicable early pk cohortsaucτ area concentrationtime curve dose interval serum tak341 predose day 1 29 57 85 169 253 337 multiple timepoint 24 hour postdose day 1 57 85 169 337 anytime day 365 427 early termination day 57 applicable early pk cohortscsf concentration tak341 lumbar puncture csf sampling perform predose day 1 85 applicable early pk cohort 365number participant adverse event ae adverse event ae define untoward medical occurrence participant administer pharmaceutical product untoward medical occurrence necessarily causal relationship treatment datum report number participant analyze safety parameter include clinically significant abnormal value clinical laboratory evaluation vital sign ecg parameters physical examination neurological examination columbiasuicide severity rating scale cssrs 52 weeksnumber participant antidrug antibody 52 week',

]

embeddings = model.encode(sentences)

print(embeddings.shape)

# [3, 384]



# Get the similarity scores for the embeddings

similarities = model.similarity(embeddings, embeddings)

print(similarities.shape)

# [3, 3]

```

<!--
### Direct Usage (Transformers)

<details><summary>Click to see the direct usage in Transformers</summary>

</details>
-->

<!--
### Downstream Usage (Sentence Transformers)

You can finetune this model on your own dataset.

<details><summary>Click to expand</summary>

</details>
-->

<!--
### Out-of-Scope Use

*List how the model may foreseeably be misused and address what users ought not to do with the model.*
-->

<!--
## Bias, Risks and Limitations

*What are the known or foreseeable issues stemming from this model? You could also flag here known failure cases or weaknesses of the model.*
-->

<!--
### Recommendations

*What are recommendations with respect to the foreseeable issues? For example, filtering explicit content.*
-->

## Training Details

### Training Dataset

#### Unnamed Dataset


* Size: 92,934 training samples
* Columns: <code>Text1</code> and <code>Text2</code>
* Approximate statistics based on the first 1000 samples:
  |         | Text1                                                                                | Text2                                                                               |
  |:--------|:-------------------------------------------------------------------------------------|:------------------------------------------------------------------------------------|
  | type    | string                                                                               | string                                                                              |
  | details | <ul><li>min: 29 tokens</li><li>mean: 104.36 tokens</li><li>max: 256 tokens</li></ul> | <ul><li>min: 8 tokens</li><li>mean: 227.98 tokens</li><li>max: 256 tokens</li></ul> |
* Samples:
  | Text1                                                                                                                                                                                                                                                                                                                               | Text2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
  |:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
  | <code>study people normal kidney function people reduce kidney function test bi 1467335 process body. The primary objective of the current study is to investigate the influence of moderate renal impairment on the pharmacokinetics of multiple doses in comparison to a matched control group with normal renal function.</code> | <code>Renal Insufficiency|Healthy inclusion criterion despite moderate renal impairment group 1 healthy male female subject accord assessment investigator base complete medical history include physical examination vital sign blood pressure bp pulse rate pr 12lead electrocardiogram ecg clinical laboratory test estimate glomerular filtration rate egfr base ckdepi formula group 1 30 59 mlmin173m2 group 2   90 mlmin173m2 age 18 79 year incl bmi 185 34 kgm2 incl sign date write inform consent prior admission study accordance good clinical practice gcp local legislation male subject female subject meet follow criterion accord ctfg recommendation relate contraception pregnancy testing clinical trial method failure rate 1 year start 30 day administration trial medication 30 day trial completion eg    use adequate contraception eg follow method plus condom implant injectable combine oral vaginal contraceptive inhibition ovulation   hormonal intrauterine device   sexually abstinent define refrain hete...</code> |
  | <code>16w interventional study titration doseefficacy assessment exelon chinese alzheimers disease patient. To investigate the efficacy of Exelon capsule at maximal tolerated dose in mild to moderate Chinese AD patients via dosage titration from 3mg/d to 12mg/d in a 16 weeks duration</code>                                 | <code>Alzheimer's Disease key inclusion criterion diagnosis dementia alzheimers type accord dsmiv criterion clinical diagnosis probable ad accord nincdsadrda criteria mmse score   10   26 treatment naïve patient stop donepezil galantamine huperzine memantine 2 week stable medical condition sign inform consent form patient hisher legal guardiankey exclusion criterion severe ad patient history cerebrovascular disease active uncontrolled epilepsy active hypothyroidism asthma cns infection neurodegenerative disorder advanced severe progressive unstable medical condition attend clinical trial take clinical trial drug score   4 modify hachinski ischemic scale mhis patient achei memantine mean change baseline alzheimer disease assessment scale   cognitive subscale adascog alzheimer disease assessment scale   cognitive subscale adascog measure change cognitive function alzheimer disease assessment scale adas scale measure specific cognitive behavior disorder alzheimer disease ad patient alzheimer di...</code> |
  | <code>case series saneso 360 gastroscope. To confirm the procedural performance of the Saneso 360° gastroscope in Esophago-gastro-duodenoscopy (EGD) procedures.</code>                                                                                                                                                             | <code>EGD Procedure inclusion criterion 18 74 year age willing able comply study procedure provide write inform consent participate study schedule clinically indicate routine egd procedure asa class 13exclusion criterion alter esophageal gastric duodenal anatomy pregnant woman child 18 year age adult 75 year age subject routine endoscopic procedure contraindicate comorbid medical condition patient currently enrol investigational study directly interfere current study prior write approval sponsor asa class 45 successful egd procedure success assess end procedure 1 procedure success define successful intubation portion duodenum photograph portion duodenum take 24 hour study day endoscopist qualitative rating saneso 360 gastroscope endoscopist rate experience saneso 360 gastroscope immediately follow completion study procedure 1 fivepoint likert scale 5   excellent 4   good 3 acceptable 2 difficult 1unacceptable 24 hour study dayendoscopist qualitative rating saneso 360 gastroscope compare past...</code> |
* Loss: [<code>MatryoshkaLoss</code>](https://sbert.net/docs/package_reference/sentence_transformer/losses.html#matryoshkaloss) with these parameters:
  ```json

  {

      "loss": "MultipleNegativesRankingLoss",

      "matryoshka_dims": [

          384,

          256,

          128,

          64

      ],

      "matryoshka_weights": [

          1,

          1,

          1,

          1

      ],

      "n_dims_per_step": -1

  }

  ```

### Training Hyperparameters
#### Non-Default Hyperparameters

- `per_device_train_batch_size`: 16
- `learning_rate`: 2e-05
- `num_train_epochs`: 1
- `warmup_ratio`: 0.1
- `fp16`: True
- `batch_sampler`: no_duplicates



#### All Hyperparameters

<details><summary>Click to expand</summary>



- `overwrite_output_dir`: False

- `do_predict`: False
- `eval_strategy`: no
- `prediction_loss_only`: True
- `per_device_train_batch_size`: 16
- `per_device_eval_batch_size`: 8
- `per_gpu_train_batch_size`: None
- `per_gpu_eval_batch_size`: None
- `gradient_accumulation_steps`: 1
- `eval_accumulation_steps`: None
- `torch_empty_cache_steps`: None
- `learning_rate`: 2e-05
- `weight_decay`: 0.0
- `adam_beta1`: 0.9
- `adam_beta2`: 0.999
- `adam_epsilon`: 1e-08
- `max_grad_norm`: 1.0
- `num_train_epochs`: 1
- `max_steps`: -1
- `lr_scheduler_type`: linear
- `lr_scheduler_kwargs`: {}
- `warmup_ratio`: 0.1
- `warmup_steps`: 0
- `log_level`: passive
- `log_level_replica`: warning
- `log_on_each_node`: True
- `logging_nan_inf_filter`: True
- `save_safetensors`: True
- `save_on_each_node`: False
- `save_only_model`: False
- `restore_callback_states_from_checkpoint`: False
- `no_cuda`: False
- `use_cpu`: False
- `use_mps_device`: False
- `seed`: 42
- `data_seed`: None
- `jit_mode_eval`: False
- `use_ipex`: False
- `bf16`: False
- `fp16`: True
- `fp16_opt_level`: O1
- `half_precision_backend`: auto
- `bf16_full_eval`: False
- `fp16_full_eval`: False
- `tf32`: None
- `local_rank`: 0
- `ddp_backend`: None
- `tpu_num_cores`: None
- `tpu_metrics_debug`: False
- `debug`: []
- `dataloader_drop_last`: False
- `dataloader_num_workers`: 0
- `dataloader_prefetch_factor`: None
- `past_index`: -1
- `disable_tqdm`: False
- `remove_unused_columns`: True
- `label_names`: None
- `load_best_model_at_end`: False
- `ignore_data_skip`: False
- `fsdp`: []
- `fsdp_min_num_params`: 0
- `fsdp_config`: {'min_num_params': 0, 'xla': False, 'xla_fsdp_v2': False, 'xla_fsdp_grad_ckpt': False}

- `fsdp_transformer_layer_cls_to_wrap`: None
- `accelerator_config`: {'split_batches': False, 'dispatch_batches': None, 'even_batches': True, 'use_seedable_sampler': True, 'non_blocking': False, 'gradient_accumulation_kwargs': None}
- `deepspeed`: None
- `label_smoothing_factor`: 0.0
- `optim`: adamw_torch

- `optim_args`: None
- `adafactor`: False
- `group_by_length`: False
- `length_column_name`: length
- `ddp_find_unused_parameters`: None
- `ddp_bucket_cap_mb`: None
- `ddp_broadcast_buffers`: False
- `dataloader_pin_memory`: True
- `dataloader_persistent_workers`: False
- `skip_memory_metrics`: True
- `use_legacy_prediction_loop`: False
- `push_to_hub`: False
- `resume_from_checkpoint`: None
- `hub_model_id`: None
- `hub_strategy`: every_save

- `hub_private_repo`: None

- `hub_always_push`: False

- `gradient_checkpointing`: False
- `gradient_checkpointing_kwargs`: None
- `include_inputs_for_metrics`: False
- `include_for_metrics`: []
- `eval_do_concat_batches`: True
- `fp16_backend`: auto
- `push_to_hub_model_id`: None
- `push_to_hub_organization`: None
- `mp_parameters`: 
- `auto_find_batch_size`: False
- `full_determinism`: False
- `torchdynamo`: None
- `ray_scope`: last
- `ddp_timeout`: 1800
- `torch_compile`: False
- `torch_compile_backend`: None
- `torch_compile_mode`: None
- `dispatch_batches`: None
- `split_batches`: None
- `include_tokens_per_second`: False
- `include_num_input_tokens_seen`: False
- `neftune_noise_alpha`: None
- `optim_target_modules`: None
- `batch_eval_metrics`: False
- `eval_on_start`: False
- `use_liger_kernel`: False
- `eval_use_gather_object`: False
- `average_tokens_across_devices`: False
- `prompts`: None
- `batch_sampler`: no_duplicates

- `multi_dataset_batch_sampler`: proportional

</details>

### Training Logs
| Epoch  | Step | Training Loss |
|:------:|:----:|:-------------:|
| 0.0861 | 500  | 2.1564        |
| 0.1721 | 1000 | 1.6731        |
| 0.2582 | 1500 | 1.3615        |
| 0.3443 | 2000 | 1.331         |
| 0.4304 | 2500 | 1.2666        |
| 0.5164 | 3000 | 1.1645        |
| 0.6025 | 3500 | 1.159         |
| 0.6886 | 4000 | 1.0752        |
| 0.7747 | 4500 | 1.0458        |
| 0.8607 | 5000 | 1.0803        |
| 0.9468 | 5500 | 1.0237        |


### Framework Versions
- Python: 3.10.12
- Sentence Transformers: 3.3.1
- Transformers: 4.48.1
- PyTorch: 2.1.0a0+32f93b1
- Accelerate: 1.3.0
- Datasets: 3.2.0
- Tokenizers: 0.21.0

## Citation

### BibTeX

#### Sentence Transformers
```bibtex

@inproceedings{reimers-2019-sentence-bert,

    title = "Sentence-BERT: Sentence Embeddings using Siamese BERT-Networks",

    author = "Reimers, Nils and Gurevych, Iryna",

    booktitle = "Proceedings of the 2019 Conference on Empirical Methods in Natural Language Processing",

    month = "11",

    year = "2019",

    publisher = "Association for Computational Linguistics",

    url = "https://arxiv.org/abs/1908.10084",

}

```

#### MatryoshkaLoss
```bibtex

@misc{kusupati2024matryoshka,

    title={Matryoshka Representation Learning},

    author={Aditya Kusupati and Gantavya Bhatt and Aniket Rege and Matthew Wallingford and Aditya Sinha and Vivek Ramanujan and William Howard-Snyder and Kaifeng Chen and Sham Kakade and Prateek Jain and Ali Farhadi},

    year={2024},

    eprint={2205.13147},

    archivePrefix={arXiv},

    primaryClass={cs.LG}

}

```

#### MultipleNegativesRankingLoss
```bibtex

@misc{henderson2017efficient,

    title={Efficient Natural Language Response Suggestion for Smart Reply},

    author={Matthew Henderson and Rami Al-Rfou and Brian Strope and Yun-hsuan Sung and Laszlo Lukacs and Ruiqi Guo and Sanjiv Kumar and Balint Miklos and Ray Kurzweil},

    year={2017},

    eprint={1705.00652},

    archivePrefix={arXiv},

    primaryClass={cs.CL}

}

```

<!--
## Glossary

*Clearly define terms in order to be accessible across audiences.*
-->

<!--
## Model Card Authors

*Lists the people who create the model card, providing recognition and accountability for the detailed work that goes into its construction.*
-->

<!--
## Model Card Contact

*Provides a way for people who have updates to the Model Card, suggestions, or questions, to contact the Model Card authors.*
-->